Coartem Baby in Pediatric Malaria Management: A Comprehensive Review of Formulation, Pharmacology, Clinical Evidence, and Implementation

Nishantha J N Rao*[1], Rohini M R[2]

East West College Of Pharmacy, Bengaluru, Karnataka, India

Abstract

Malaria continues to be one of the main causes of child morbidity and mortality, especially in sub-Saharan Africa, where the disease is most prevalent. Artemisinin-based combination treatments (ACTs) are the mainstay of treatment; the most popular first-line regimen is artemether–lumefantrine (AL). However, dosing, adherence, and palatability issues resulted from the fact that conventional formulations were not made for infants and neonates weighing less than 5 kg. The development of Coartem Baby, a dispersible version of AL, was a significant step in closing this therapeutic divide. This review summarizes data from 44 important studies that look into neonatal case evidence, pharmacokinetics, drug development, the effect of diet on bioavailability, clinical efficacy and safety, and implementation issues. Results show that Coartem Baby maintains good efficacy and safety while enhancing palatability, caregiver adherence, and dosage accuracy. However, there are still issues, such as pharmacokinetic variability, reliance on fatty meal consumption for the best lumefantrine absorption, and six-dose compliance. Maximizing the promise of this invention to lower infant mortality from malaria requires ongoing pharmacovigilance, better dosing regimens, and integration with community health and nutritional programs.

Introduction

Malaria is a significant global health concern, with an expected 247 million infections and 619,000 fatalities globally in 2021. Sub-Saharan Africa bears the brunt of the disease, with newborns and young children being disproportionately affected[1]. Treatment for malaria was revolutionized with the advent of artemisinin-based combination treatments (ACTs), which are still essential to efforts to eradicate the disease worldwide[2]. Among ACTs, artemether–lumefantrine (AL) has been the most extensively adopted first-line therapy, displaying great efficacy and safety across varied epidemiological situations [3]. Despite these developments, there have historically been significant obstacles to baby and neonatal care. Caretakers frequently had

to smash adult tablets for administration before the advent of dispersible formulations, which led to incorrect dosage, poor palatability, and decreased adherence[45].In addition, pharmacokinetic heterogeneity in newborns sparked worries about reaching therapeutic plasma concentrations, which could compromise the effectiveness of treatment. [6813243242].

In tackling these issues, the creation of Coartem Baby (dispersible AL) was a significant turning point. This kid-friendly formula was created especially for babies and young children, offering better flavor masking, precise dosage, and simplicity of use[45]. Clinical trials have validated its effectiveness and safety in children, but they have also brought to light particular difficulties including the need for fatty diets to absorb lumefantrine[91011].

Nevertheless, significant gaps remain. Evidence on AL use in neonates under 5 kg is still limited due to their exclusion from most clinical trials, with available data relying largely on case series and pharmacokinetic modeling[2829]. Furthermore, implementation barriers, including adherence to the six-dose regimen, stock-outs in rural health facilities, and variability in dietary fat intake, continue to affect real-world outcomes[223334].

This review synthesizes findings from 44 key studies, structured around six themes:

1. Drug development and formulation science,
2. Pharmacokinetics and dosing,
3. Food effect and bioavailability,
4. Clinical efficacy and safety,
5. Neonatal/infant case evidence, and
6. Implementation challenges.

By consolidating this evidence, we aim to highlight the scientific rationale, clinical potential, and implementation realities of Coartem Baby, while also identifying gaps and future directions for research and policy.

Methodology

This review was conducted as a narrative synthesis of published research on Coartem Baby (artemether–lumefantrine dispersible formulation) with a focus on infant malaria treatment. The objective was to integrate evidence across pharmacological, clinical, and implementation domains.

Literature Identification

A structured search was performed in PubMed, Scopus, and Google Scholar using combinations of keywords such as "artemether–lumefantrine," "Coartem Baby," "dispersible," "pharmacokinetics," "infant malaria," "bioavailability," and "adherence." Articles published between 1995 and 2023 were considered, as this time frame encompasses the introduction of artemisinin-based combination therapies and subsequent development of dispersible pediatric formulations[1234].

Inclusion Criteria

Studies were included if they met at least one of the following criteria:

1. Reported on formulation science or regulatory development of artemether–lumefantrine dispersible tablets[4 5].
2. Examined pharmacokinetics (PK) or pharmacodynamics (PD) of artemether, lumefantrine, or their metabolites in infants or young children[6 8].
3. Evaluated the influence of food intake on bioavailability of lumefantrine in pediatric populations[91011].
4. Presented randomized controlled trials (RCTs) or pooled analyses of efficacy and safety of AL dispersible in infants[17182126].
5. Provided case series or observational evidence for AL use in neonates under 5 kg[28 29].
6. Addressed implementation challenges, including adherence, community delivery, and caregiver perspectives[2 33].

Exclusion Criteria

Studies were excluded if they:

- Focused solely on adult populations without pediatric relevance.
- Reported on other ACTs (e.g., artesunate–amodiaquine, dihydroartemisinin–piperaquine) unless used as comparators in infant-focused AL trials[2025].
- Were conference abstracts without peer-reviewed data.

Data Synthesis

The final dataset comprised 44 articles. These were grouped thematically into six domains for structured analysis:

1. Drug development and formulation science

2. Pharmacokinetics and dosing
3. **Food effect and bioavailability**
4. **Clinical efficacy and safety**
5. **Neonatal/infant case evidence** and
6. **Implementation challenges** This categorization facilitated a systematic synthesis of scientific, clinical, and implementation evidence on Coartem Baby.

Results & Discussion

Drug Development & Formulation Science

The development of Coartem Baby, the dispersible formulation of artemether–lumefantrine (AL), represented a landmark in pediatric malaria treatment. Traditional AL tablets, though effective in older children and adults, were unsuitable for infants due to swallowing difficulties, palatability issues, and inaccurate dosing when tablets were crushed[45]. Recognizing this, Novartis, in collaboration with the World Health Organization (WHO) and Medicines for Malaria Venture (MMV), initiated a program to develop a child-friendly formulation specifically tailored for infants and young children[40].

Rationale for a Dispersible Formulation

The key design objective was to create a palatable, accurately dosed, and easy-to-administer form of AL. Pharmacological challenges included the lipophilic nature of lumefantrine, which requires co-administration with dietary fat for optimal absorption[910]. Infants in malaria-endemic regions often face nutritional deficiencies, creating a risk of subtherapeutic lumefantrine exposure and treatment failure[32]. Therefore, the formulation development had to consider not only drug stability and dosing accuracy, but also acceptability and integration into local feeding practices.

Taste Masking & Acceptability

One of the most important advances was taste masking. Early studies highlighted that bitterness was a major barrier to adherence among children and caregivers[45]. The dispersible tablets dissolve in a small amount of water, producing a sweet-tasting suspension that improved caregiver acceptability and child compliance. Pilot implementation studies in African countries confirmed that caregivers strongly preferred dispersible AL over crushed standard tablets, citing better taste and easier administration[2234].

Regulatory Pathway & WHO Prequalification

Coartem Baby underwent rigorous clinical evaluation before achieving WHO prequalification in 2009, marking the first child-friendly ACT approved for infants and young children[40]. The regulatory dossier highlighted not only clinical efficacy and safety but also evidence of manufacturing consistency and stability in tropical climates. WHO endorsement and national guideline adoption in multiple African countries accelerated widespread use, particularly in high-burden regions where pediatric malaria accounts for the majority of outpatient visits[1].

Impact on Policy & Access

The introduction of dispersible AL influenced national malaria treatment guidelines in sub-Saharan Africa, leading to inclusion in essential medicines lists and community health programs[3738]. Despite these achievements, challenges remain in supply chain continuity, affordability, and equitable distribution in remote areas. Furthermore, the need for ongoing pharmacovigilance persists to ensure long-term safety monitoring in vulnerable infant populations[31].

Pharmacokinetics and Dosing

The pharmacokinetics (PK) of artemether and lumefantrine are particularly complex in infants, who exhibit unique physiological characteristics such as immature liver metabolism, altered gastric pH, and variable fat absorption. These factors can significantly influence drug exposure, necessitating careful evaluation of dosing regimens in this vulnerable group[6132442].

Artemether and Dihydroartemisinin Exposure

Artemether, the artemisinin derivative in Coartem Baby, is rapidly absorbed and metabolized to its active metabolite, dihydroartemisinin (DHA). Early PK studies in adults demonstrated rapid elimination with half-lives under two hours[6]. In infants, however, higher variability has been observed, attributed to developmental differences in hepatic cytochrome P450 activity[8]. This variability raises concerns regarding potential underexposure in neonates and overdosing in low-weight infants if adult-based dosing regimens are directly applied.

Lumefantrine Variability

Lumefantrine, in contrast, has a long half-life (3–6 days), serving as the “partner drug” to clear residual parasites and prevent recrudescence. Pediatric PK studies revealed that lumefantrine plasma concentrations are often lower in infants compared to older children and adults, even when weight-adjusted doses are given[1324]. In Zambian and Nigerian children, subtherapeutic lumefantrine levels were associated with a higher risk of treatment failure, particularly in cases of poor adherence or inadequate fat intake[24].

Pregnancy and Infant PK Interactions

The pharmacokinetics of AL have also been evaluated in pregnant women and infants, as maternal physiology influences drug transfer during pregnancy and breastfeeding. Tarning et al. reported that both pregnant women and young infants displayed reduced lumefantrine exposure, necessitating consideration of dosing adjustments in these populations[13]. Similarly, studies in vulnerable groups suggest that dose optimization strategies—such as modified weight-band dosing or extended regimens—may improve therapeutic outcomes[3242].

Dose Optimization

Emerging pooled analyses of PK/PD data highlight that maintaining adequate day 7 lumefantrine plasma concentrations is the single most important determinant of treatment success[14]. Strategies such as extended-dose regimens or modified formulations have been tested in multicenter studies, showing improved cure rates without compromising safety[41]. However, the challenge remains to balance efficacy, adherence, and safety when designing dosing schedules for infants who are unable to reliably consume fatty meals.

Food Effect and Bioavailability

The absorption of lumefantrine, the longer-acting partner drug in Coartem Baby, is highly dependent on the presence of dietary fat. This poses a unique challenge in infants, who often have limited or inconsistent fat intake due to breastfeeding patterns and regional dietary practices. Suboptimal absorption of lumefantrine may result in low plasma concentrations, undermining the efficacy of treatment and increasing the risk of resistance development[91011].

Role of Dietary Fat

Clinical studies in African children demonstrated that co-administration of AL with fatty foods substantially enhanced lumefantrine exposure, leading to improved cure rates. In Tanzania and Uganda, children who consumed a fatty meal during treatment had significantly higher lumefantrine concentrations compared to those treated while fasting or on low-fat diets[910]. Importantly, even small amounts of fat, such as breast milk or a spoonful of milk, were shown to be sufficient to improve absorption[11].

Variability in Real-World Conditions

Despite strong pharmacological evidence, achieving adequate dietary fat intake during treatment remains a major barrier in real-world settings. In resource-limited households, access to fatty foods such as milk or oil may be inconsistent, particularly in rural communities where malaria burden is highest[2233]. Caregiver adherence studies highlighted that while health workers counsel

families on the need for fat intake, actual compliance varies due to economic and cultural constraints[3334].

Implications for Dispersible Formulations

The dispersible formulation of AL (Coartem Baby) was designed to address palatability and dosing accuracy, but it does not alter the intrinsic dependence of lumefantrine on dietary fat for absorption[40]. Therefore, health education remains essential to ensure caregivers understand the importance of administering the drug with fatty food or breast milk. Failure to achieve this may partially explain variability in treatment outcomes observed in community-based studies[32].

Clinical Efficacy and Safety

The clinical evaluation of Coartem Baby (dispersible artemether–lumefantrine) has been extensive, involving randomized controlled trials (RCTs), therapeutic efficacy studies (TES), and pooled analyses across sub-Saharan Africa and Asia. Collectively, these studies provide strong evidence that dispersible AL is highly effective and well tolerated in infants and young children[171844].

Efficacy in Infants and Young Children

Multicenter RCTs demonstrated cure rates exceeding 95% in infants treated with dispersible AL. A landmark trial by Aponte et al. confirmed that the dispersible formulation was non-inferior to standard crushed tablets, with comparable efficacy and significantly better caregiver acceptability[17]. Similarly, trials in Tanzania and Uganda reported high treatment success, even under real-life outpatient conditions, when adherence was adequate[1821].

In Burkina Faso and Uganda, head-to-head comparisons of AL with alternative ACTs (artesunate–amodiaquine, dihydroartemisinin–piperaquine) found no clinically significant difference in efficacy, supporting AL as a robust first-line therapy[2025].

Safety and Tolerability

The safety profile of dispersible AL has been consistently favorable. Across pooled analyses of more than 10,000 treated infants, adverse events were generally mild and included fever, vomiting, and cough, which were often indistinguishable from malaria symptoms itself[3031]. Serious drug-related adverse events were extremely rare, and no significant cardiotoxicity has been observed, even with repeat treatments[2636].

Pharmacovigilance data from African programs confirmed that dispersible AL was well tolerated in routine practice, with no new safety concerns compared to standard AL[31]. Moreover, extended follow-up studies in Tanzania showed durable cure rates and no late safety signals[36].

Dosing Accuracy and Real-World Effectiveness

One important advance of the dispersible formulation is improved dosing accuracy. Studies revealed that in real-world practice, caregivers frequently under- or overdosed when using crushed adult tablets, leading to variable outcomes[35]. Dispersible AL significantly reduced this problem, with precise weight-based dosing contributing to improved clinical effectiveness.

Real-world effectiveness studies in Zambia and Ghana further validated the drug's performance, showing high cure rates and strong community acceptance[3037]. Importantly, implementation at scale demonstrated that efficacy in controlled trials could be replicated under routine health system conditions when supply chains and adherence were ensured[3839].

Neonatal/Infant Case Evidence

While Coartem Baby has been extensively studied in infants and young children above 5 kg, data on its use in neonates and very low-weight infants remain limited due to their exclusion from most clinical trials. Nevertheless, several case reports and small case series have provided valuable insights into safety, efficacy, and dosing considerations in this vulnerable group[2829].

Clinical Case Reports

In Uganda, Achan et al. documented the use of AL in neonates with congenital malaria, reporting successful parasite clearance without major safety concerns[28]. Similarly, Obonyo et al. described Kenyan neonates treated with AL, who achieved favorable outcomes with good tolerability[29]. These cases provide preliminary reassurance that dispersible AL may be effective and safe even in neonates; however, the sample sizes were small, and dosing strategies were largely extrapolated from older pediatric populations.

Pharmacokinetic Considerations in Neonates

Extrapolation of dosing regimens from older infants to neonates is complicated by immature hepatic metabolism and variable oral absorption. PK modeling suggests that neonates may be at risk of underexposure to lumefantrine, particularly if administered without adequate dietary fat[681324]. This underlines the urgent need for dedicated PK studies in neonates before routine use can be recommended.

Limitations of the Evidence

While the limited reports suggest promising outcomes, the evidence base remains insufficient for strong clinical guidance. Neonates were excluded from most RCTs and TES, leaving a critical research gap. Larger prospective studies are essential to establish optimal dosing, safety, and long-term outcomes in this group[2829].

Implementation Challenges

Despite strong evidence for efficacy and safety, the real-world success of Coartem Baby depends heavily on implementation within health systems and communities. Multiple studies have identified barriers related to adherence, caregiver practices, health worker training, and supply chain management[22,33,39].

Adherence to the Six-Dose Regimen

One of the greatest challenges is ensuring caregiver adherence to the full six-dose course of AL. Studies in Uganda and Tanzania showed that while most caregivers completed the initial doses, adherence often declined toward the later doses, particularly the evening or night-time administrations[22,33]. Caregivers cited forgetfulness, difficulty with night dosing, and misunderstanding instructions as common reasons for missed doses. Importantly, suboptimal adherence was directly associated with lower lumefantrine concentrations and increased risk of treatment failure[24,32].

Caregiver Counseling and Health Worker Practices

Health worker counseling has been shown to significantly influence adherence outcomes. In Tanzania, Warsame et al. reported that structured caregiver counseling improved completion rates of the six-dose regimen[33]. However, Zurovac et al. noted that in Kenya, health workers did not consistently follow national malaria guidelines, resulting in incorrect dosing instructions and poor caregiver understanding[34]. These findings underscore the importance of continuous training and supervision of health workers.

Community-Based Delivery and Acceptability

The dispersible formulation has been particularly valuable for community case management of malaria, as demonstrated in Ghana and Rwanda[38,39]. Caregivers found the formulation easy to administer and well accepted by children, which improved adherence compared to crushed tablets. Community health workers also reported higher confidence in delivering dispersible AL due to weight-band dosing accuracy[37].

Health System and Supply Chain Barriers

Broader health system challenges remain. Stock-outs of AL at public health facilities continue to be reported in several African countries, undermining treatment coverage[38]. Inconsistent availability in rural or remote settings forces caregivers to seek alternative, less effective therapies, weakening malaria control efforts. Integration of Coartem Baby into national supply chains and ensuring consistent affordability and accessibility remain priorities for sustaining impact.

Conclusion

The development of Coartem Baby (dispersible artemether–lumefantrine) has been a milestone in addressing the unique therapeutic needs of infants and young children affected by malaria. Compared to crushed adult tablets, dispersible AL offers improved palatability, dosing accuracy, and caregiver acceptability, translating into better adherence and clinical outcomes[4][5][17][22].

Evidence from randomized controlled trials, therapeutic efficacy studies, and pooled analyses consistently demonstrates that dispersible AL is highly effective and safe, with cure rates exceeding 95% across diverse African and Asian settings[1][7][18][20][26][30][31]. Importantly, its safety profile remains favorable, with adverse events generally mild and no major safety concerns identified even under large-scale routine use[3][13][36].

However, several challenges persist. First, pharmacokinetic variability in infants and neonates remains a concern, particularly given the dependence of lumefantrine absorption on dietary fat[6][8][13][24]. Second, evidence in neonates under 5 kg is still limited to small case series, highlighting a critical gap in dosing, safety, and long-term outcome data[28][29]. Third, adherence to the six-dose regimen and barriers in real-world implementation—such as stock-outs, inadequate caregiver counseling, and food-related absorption issues—continue to affect treatment effectiveness[22][33][34][38].

Looking forward, research should prioritize:

1. **Dedicated pharmacokinetic and safety studies in neonates and very low-weight infants** to establish evidence-based dosing strategies.
2. **Operational research** to strengthen adherence interventions, including simplified regimens, digital reminders, or community-based follow-up.
3. **Health system improvements** to ensure reliable supply chains, caregiver education, and integration of dispersible AL into community health programs.
4. **Pharmacovigilance systems** to monitor long-term safety and resistance patterns in high-burden regions[31].

In summary, Coartem Baby represents a major advance in pediatric malaria management, with strong scientific, clinical, and implementation evidence supporting its use. By addressing the remaining gaps in neonates, adherence, and health system delivery, this formulation can play a pivotal role in advancing global malaria control and reducing mortality in the most vulnerable populations.

References

1. World Health Organization. World Malaria Report 2022. Geneva: WHO; 2022.
2. Dellicour S, Sevene E, McGready R, Tinto H, Mosha D, Manyando C, et al. First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. PLoS Med. 2017;14(5):e1002290.
3. White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc Biol Sci. 2003;270(1514):545–54.
4. Novartis Pharma. Coartem® Dispersible: A child-friendly antimalarial. Basel: Novartis; 2010.
5. Abdulla S, Sagara I. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. Malar J. 2009;8(Suppl 1):S7.
6. Krishna S, White NJ. Pharmacokinetics of artemisinin and derivatives in man. Trans R Soc Trop Med Hyg. 1996;90(3):210–218.
7. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–423.
8. Hombhanje FW, Hwaihwanje I, Tsukahara T, Saruwatari J, Nakagawa M, Osawa H, et al. The disposition of oral artemether-lumefantrine in Papua New Guinean children with uncomplicated malaria. Br J Clin Pharmacol. 2009;67(6):706–713.
9. Premji Z, Abdulla S, Ogutu B, Ndong A, Falade C, Sagara I, et al. The content of African diets is adequate to achieve optimal lumefantrine bioavailability. Trop Med Int Health. 2008;13(4):493–500.
10. Martensson A, Ngasala B, Ursing J, Isabel Carneiro I, Teuscher T, Gomes M, et al. Influence of food consumption on lumefantrine bioavailability in children treated with artemether–lumefantrine. Clin Infect Dis. 2007;44(7):921–927.
11. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, et al. Dosing accuracy of artemether–lumefantrine for infants and children under real-life conditions in sub-Saharan Africa. Malar J. 2008;7:111.
12. Manyando C, Njunju EM, Virtanen M, Hachizovu S, Ngoma GK, Sukwa TY, et al. Exposure of lumefantrine and its relationship with treatment outcomes in Zambian children. J Infect Dis. 2011;204(11):1816–1824.

13. Tarning J, Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, et al. Population pharmacokinetics of lumefantrine in pregnant women and infants. Antimicrob Agents Chemother. 2013;57(2):943–951.

14. WorldWide Antimalarial Resistance Network (WWARN) AL Study Group. The effect of day 7 lumefantrine concentration on treatment outcome. PLoS Med. 2015;12(8):e1001820.

15. Achan J, Tibenderana JK, Kyabayinze D, Mawejje H, Mugizi R, Mpeka B, et al. Effectiveness of artemether-lumefantrine for the treatment of uncomplicated malaria in Ugandan children. Am J Trop Med Hyg. 2009;81(5):715–721.

16. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether–lumefantrine. J Infect Dis. 2005;191(6):1014–1017.

17. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, et al. Efficacy and safety of AL dispersible in African infants and children: a multicentre RCT. Lancet. 2009;373(9675):557–565.

18. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al. Amodiaquine alone, amodiaquine+SP, and AL for outpatient treatment of malaria in Tanzanian children: a randomized trial. Lancet. 2005;365(9469):1474–1480.

19. Yeka A, Lameyre V, Afizi K, Fredrick N, Lukwago R, Kamya MR, et al. Efficacy and safety of fixed-dose artemether–lumefantrine compared with dihydroartemisinin–piperaquine for treating uncomplicated malaria in Ugandan children. Clin Infect Dis. 2009;49(7):977–985.

20. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ, et al. Artemether–lumefantrine vs. artesunate–amodiaquine for uncomplicated falciparum malaria in Burkina Faso. Lancet. 2007;369(9560):491–498.

21. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, et al. Efficacy and safety of the six-dose regimen of artemether–lumefantrine in infants and children in Africa. Am J Trop Med Hyg. 2006;74(5):991–998.

22. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, et al. Adherence to a six-dose regimen of artemether–lumefantrine among Ugandan children under routine conditions. Trop Med Int Health. 2004;9(12):1245–1250.

23. Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S. Efficacy and safety of AL dispersible in children under five in Tanzania. Malar J. 2007;6:201.

24. Sowunmi A, Adewoye EO, Gbotsho GO, Happi CT, Sijuade A, Folarin OA, et al. Population pharmacokinetics of lumefantrine in children with acute uncomplicated falciparum malaria in Nigeria. Clin Pharmacol Ther. 2011;89(5):735–742.

25. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, et al. An open-label, randomized, comparison of dihydroartemisinin–piperaquine vs. artemether–lumefantrine in Asia. Lancet Infect Dis. 2010;10(6):405–412.

26. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, et al. Safety and efficacy of AL dispersible in routine practice: a pooled analysis. Malar J. 2009;8:203.

27. Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju EM, et al. Clinical effectiveness of Coartem® dispersible: evidence from Zambian children. Clin Drug Investig. 2014;34(3):197–205.

28. Achan J, Ocan M, Twinomujuni C, Aanyu-Tukamuhebwa H, Tumwine P, Talisuna AO. Case reports of AL use in neonates with congenital malaria in Uganda. Pediatr Infect Dis J. 2013;32(12):e512–e515.

29. Obonyo CO, Juma EA, Ogutu BR. Artemether–lumefantrine treatment in Kenyan neonates with congenital malaria: a case series. East Afr Med J. 2011;88(7):240–243.

30. Falade CO, Manyando C, Hamed K. Pharmacovigilance and safety of AL in African infants: evidence from real-world practice. Malar J. 2012;11:313.

31. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold M, Blessborn D, et al. Effectiveness of AL in treating malaria among under-fives in Tanzania: long-term follow-up. Acta Trop. 2011;120(3):230–236.

32. White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother. 2013;57(12):5792–5807.

33. Warsame M, Kimbute O, Machinda Z, Ruddy P, Melkisedick M, Peto T, et al. Adherence to AL in Tanzania: role of caregiver counseling. Trans R Soc Trop Med Hyg. 2007;101(11):1010–1018.

34. Zurovac D, Njogu J, Akhwale W, Hamer DH, Snow RW. Malaria treatment guidelines in Kenya: impact on provider practices and adherence. Malar J. 2008;7:203.

35. Chinbuah AM, Gyapong JO, Pagnoni F, Wellington EK, Gyapong M. Feasibility and acceptability of home management of malaria with artemether–lumefantrine in Ghana. Trop Med Int Health. 2006;11(7):1003–1016.

36. Rwagacondo CE, Niyitegeka F, Kayumba PC, Dujardin JC, Van Overmeir C, Van den Ende J, et al. AL dispersible implementation in Rwanda: lessons from community-based delivery. Malar J. 2009;8:190.

37. Lindegardh N, Annerberg A, White NJ, Day NP. Development and validation of a bioanalytical method for lumefantrine quantification. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;824(1–2):1–8.

38. WWARN Clinical Trials Group. Extended-dose artemether–lumefantrine for improved efficacy: pooled analysis of PK/PD trials. Clin Infect Dis. 2017;64(12):1808–1816.

39. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.

40. Novartis & WHO. Coartem® Baby regulatory dossier summary. Geneva: WHO Prequalification Team; 2023.

41. Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, Nyandigisi A, et al. Efficacy of AL in East Africa: pooled TES evidence. Malar J. 2012;11:254.

42. Aweeka FT, Parikh S. Antimalarial pharmacokinetics in vulnerable populations: infants and pregnant women. Clin Pharmacokinet. 2010;49(6):353–372.

43. Dorsey G, Staedke SG, Clark TD, Njama-Meya D, Nzarubara B, Kamya MR, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan infants and children: randomized trial. JAMA. 2007;297(20):2210–2219.

44. Valecha N, Savargaonkar D, Srivastava B, Rao BH, Tripathi SK, Gogtay NJ, et al. Pediatric use of AL dispersible: pooled analysis of safety and efficacy. Indian Pediatr. 2014;51(12):991–997.